Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Sélectionnez vos espèces et l'application
anti-Human BRCA1 Anticorps:
anti-Mouse (Murine) BRCA1 Anticorps:
anti-Rat (Rattus) BRCA1 Anticorps:
Vous arrivez à notre recherche pré-filtrée.
Human Monoclonal BRCA1 Primary Antibody pour ChIP, ICC - ABIN450350
Arizti, Fang, Park, Yin, Solomon, Ouchi, Aaronson, Lee: Tumor suppressor p53 is required to modulate BRCA1 expression. dans Molecular and cellular biology 2000
Show all 9 Pubmed References
Human Monoclonal BRCA1 Primary Antibody pour IHC (p), IP - ABIN445490
Bernard-Gallon, Déchelotte, Vissac, Aunoble, Cravello, Malpuech, Bignon: BRCA1 and BRCA2 protein expressions in an ovotestis of a 46, XX true hermaphrodite. dans Breast cancer research : BCR 2001
Show all 8 Pubmed References
Human Polyclonal BRCA1 Primary Antibody pour FACS, WB - ABIN151683
Zaugg, Su, Reilly, Moolani, Cheung, Hakem, Hirao, Liu, Elledge, Mak: Cross-talk between Chk1 and Chk2 in double-mutant thymocytes. dans Proceedings of the National Academy of Sciences of the United States of America 2007
Show all 7 Pubmed References
Human Polyclonal BRCA1 Primary Antibody pour IHC - ABIN965696
Kim, Xu, Kastan: Involvement of the cohesin protein, Smc1, in Atm-dependent and independent responses to DNA damage. dans Genes & development 2002
Show all 5 Pubmed References
Human BRCA1 Primary Antibody pour IHC - ABIN965694
Arlt, Xu, Durkin, Casper, Kastan, Glover: BRCA1 is required for common-fragile-site stability via its G2/M checkpoint function. dans Molecular and cellular biology 2004
Show all 5 Pubmed References
Human Monoclonal BRCA1 Primary Antibody pour ICC, FACS - ABIN152032
Okada, Ouchi: Cell cycle differences in DNA damage-induced BRCA1 phosphorylation affect its subcellular localization. dans The Journal of biological chemistry 2003
Show all 4 Pubmed References
Human Monoclonal BRCA1 Primary Antibody pour CyTOF, FACS - ABIN152030
Yin, Wei, Li, Cao, Guo: Identification and molecular characterization of a new member of the peritrophic membrane proteins from the meadow moth, loxostege sticticalis. dans International journal of biological sciences 2010
Show all 4 Pubmed References
Human Monoclonal BRCA1 Primary Antibody pour ChIP, ICC - ABIN151868
Li, Ting, Zheng, Chen, Ziv, Shiloh, Lee, Lee: Functional link of BRCA1 and ataxia telangiectasia gene product in DNA damage response. dans Nature 2000
Show all 4 Pubmed References
Polyclonal BRCA1 Primary Antibody pour IF - ABIN4948304
Scully, Livingston: In search of the tumour-suppressor functions of BRCA1 and BRCA2. dans Nature 2000
Show all 3 Pubmed References
Monoclonal BRCA1 Primary Antibody pour IF, IP - ABIN534087
Aglipay, Martin, Tawara, Lee, Ouchi: ATM activation by ionizing radiation requires BRCA1-associated BAAT1. dans The Journal of biological chemistry 2006
Show all 3 Pubmed References
Because BRCA1 is highly expressed in neuronal progenitor cells during early development and MYC is less efficient than MYCN in recruiting BRCA1, our findings indicate that a cell-lineage-specific stress response enables MYCN-driven tumours to cope with deregulated RNAPII function
BRCA1polymorphisms rs799917 and rs1799966 were not significantly associated with breast cancer risk (Meta-Analysis)
The current study identified an unreported mutation in BRCA1 (c.5512dupG) in two patients with BC from one family, a 28-year-old daughter and her mother diagnosed 2 years apart, both with TNBC. This novel mutation, along with other reported founder mutations in Saudi Arabia, may contribute to the potentially disease-associated etiology of BC in Saudi Arabia.
The germline mutational landscape of BRCA1 and BRCA2 in Brazil.
Study identified rare single nucleotide variants and small indels mapping to the 5' non-coding region of BRCA1 through targeted sequencing of over 6000 early onset/familial breast cancer patients. Four variants in minimal promoter regions seem to alter gene activity; two others disrupt the binding with NFYA.
Mutations in BRCA1, BRCA2, and PALB2, and a panel of 50 cancer-associated genes in pancreatic ductal adenocarcinoma
We propose that BRCA1-CTIP and MRE11 prepare nascent DNA ends, blocked from synthesis by CTNAs, for further repair.
Data indicate that patients with a combined profile of uracil DNA glycosylase (UDG)/breast cancer 1, early onset protein (BRCA1) had the poorest outcome.
The meta-analysis results provide clinicians and health-care regulatory agencies with evidence of the increased risk of colorectal cancer in BRCA1 mutation carriers, but not in BRCA2.
BRCA1/2 genes are the most commonly mutated pancreatic cancer susceptibility genes that should be considered in all pancreatic cancer cases with young age at onset or a family history of cancer.
Detection of disease-associated variants in the BRCA1 and BRCA2 (BRCA1/2) genes allows for cancer prevention and early diagnosis in high-risk individuals.
All patients in our centre were tested using next-generation sequencing (NGS) panels that included full gene sequencing as well as coverage for large deletions/duplications in BRCA1/2. We calculated MSS1-3 scores for index patients between 2014 and 2017 who had undergone BRCA1/2 genetic testing and recorded their genetic test results
results demonstrate a relationship between BRCA1 and steroid hormones signal transduction pathways in breast cancer cells and point out to the importance of complex BRCA1 and ERa expression regulation mechanisms studies including epigenetic gene expression regulation
The estimated penetrance of breast cancer to age 80 years was 60.8% for BRCA1 and 63.1% for BRCA2. For all BRCA carriers, the penetrance of breast cancer to age 80 for those with no first-degree relative with breast cancer was 60.4% and 63.3% for those with at least 1 first-degree relative with breast cancer
Five per cent of unselected Asian patients with breast cancer carry deleterious variants in BRCA1 in Malaysia.
BRCA1 germline mutations do not predispose to the invasive lobular breast carcinoma.
findings reveal a BRCA1-mediated pathway that governs replication fork protection
BRCA1 variant (rs80356932, 4491C/T) is significantly associated with high breast cancer risk in the Pakistani population. The mutation alters the protein interactions of BRCA complex that results in tumor genesis.
Data found higher BRCA1/2 mRNA-expression in ovarian cancer (OC). BRCA1 mutated OCs exhibited lower BRCA1 but higher BRCA2 mRNA-expression. Low BRCA1-expression was associated with favorable overall survival and low BRCA2-expression with better progression-free and overall survival.
This is the largest study to date comparing outcomes in patients with EOC and BM by mutation status. mBRCA1 and mBCRA2 patients were more likely to have isolated BM, which may be a factor in their long survival.
Investigation on BRCA1 SNPs and its effects on mastitis in Chinese commercial cattle.
The gene-specific SNP marker analysis showed a significant association of BRCA1 C28300A with milk somatic cell scores.
In general, OC use, childbearing and breastfeeding do not differ between BRCA1/2 carriers and non-carriers with ovarian cancer. However, the effects of tubal ligation may differ between BRCA1 carriers and non-carriers.
Bovine BRCA1 was phosphorylated and nuclear speckling was enhanced in response to DNA-damaging agents.These results provide evidence that phosphorylation and nuclear relocalization are highly conserved features of the BRCA1 response to genotoxic stress.
Consensus-based recombinant adeno-associated virus-BRCA1 knock out virus vectors failed to induce BRCA1 knockout in Gottingen fibroblasts.
These findings uncover radiosensitivity as a novel, therapeutically viable vulnerability of BRCA1-deficient mouse mammary cells that have acquired drug resistance due to the loss of the 53BP1 pathway.
Double minute chromosomes population is reduced through the inhibition of the PI3K/Akt/BRCA1 complex pathway.
autophagy can increase the benefits of metformin treatment in BRCA1-deficient breast cancers.
The tumor suppression mechanisms of the BRCA1-PALB2 DNA damage response pathway.
his study reveals for the first time that estrogen promotes BRCA1-deficient tumor initiation and progression by stimulation of cell proliferation and activation of EMT, which are dependent on AKT activation and independent of ER.
Bard1(S563F/S563F) and Bard1(K607A/K607A) mice, unlike Brca1(S1598F/S1598F) mice, are not tumor prone, indicating that homology-directed repair alone is sufficient to suppress tumor formation in the absence of stalled fork protection
BRCA1 is involved in genetic stability of the lacrimal gland.
any condition that results in loss of Brca1 function could induce metabolic imbalance in skeletal muscle.
Pol II pausing is an important contributor to BRCA1-associated R-loop accumulation and breast cancer development.
Enhanced BRCA1 after cerebral ischemia/reperfusion njury may attenuate or prevent neural damage from ischemia/reperfusion via NRF2-mediated antioxidant pathway.
BRCA1 Interacting Protein COBRA1 Facilitates Adaptation to Castrate-Resistant Growth Conditions.
Recent work in a TP53(-/-)BRCA1-mutant murine breast cancer model indicates that double blockade with two immune checkpoint inhibitors increases the number of tumor-infiltrating lymphocytes and overall survival after DNA damaging chemotherapy, whereas single blockade does not
Data indicate the importance of breast cancer 1 protein (BRCA1)/breast cancer 2 protein (BRCA2) function in cranial neural crest cells (CNCCs) during craniofacial skeletal formation.
ATM has a role in homology-directed repair (HDR) independent of the BRCA1-53BP1 antagonism; its HDR function can become critical in certain contexts
BRCA1, but not BRCA2, suppresses the formation of tandem duplications at a site-specific chromosomal replication fork barrier imposed by the binding of Tus proteins to an array of Ter sites. BRCA1 has no equivalent role at chromosomal double-stranded DNA breaks, indicating that tandem duplications form specifically at stalled forks.
Loss of p16INK4 protein (p16) transforms breast cancer 1 (Brca1)-deficient mammary epithelial cell (MEC) and induces mammary tumors.
Brca1 is necessary for hematopoietic stem cells maintenance and normal hematopoiesis and that distinct mutations lead to different degrees of hematopoietic dysfunction.
TGFbeta stabilized the abundance of BRCA1 by reducing the abundance of microRNA-182 (miR-182). Ectopic expression of BRCA1 or antagonism of miR-182 in cultured TGFbeta-deficient mammary epithelial cells restored luminal lineage commitment.
BRCA1 inactivation can increase expression of miR-155, contributing to cardiac hypertrophy. And Rev produces their beneficial effects partially by down-regulating miR-155 expression, which might be a novel strategy for treatment of cardiac hypertrophy.
both murine Brca1185stop tumors and human BRCA1185delAG breast cancer cells express a new gene domain-less (RING-less) BRCA1 protein that mediated resistance to homologous recombination deficient-targeted therapies
MRN (Mre11, Rad50, and Nbs1) complex, CtIP, and BRCA1 are required for both the removal of Top2-DNA adducts and the subsequent resection of Top2-adducted DSB ends.
BRCA1-dependent helicase unloading is a critical, early event in DNA interstrand crosslink repair.
This gene encodes a nuclear phosphoprotein that plays a role in maintaining genomic stability, and it also acts as a tumor suppressor. The encoded protein combines with other tumor suppressors, DNA damage sensors, and signal transducers to form a large multi-subunit protein complex known as the BRCA1-associated genome surveillance complex (BASC). This gene product associates with RNA polymerase II, and through the C-terminal domain, also interacts with histone deacetylase complexes. This protein thus plays a role in transcription, DNA repair of double-stranded breaks, and recombination. Mutations in this gene are responsible for approximately 40% of inherited breast cancers and more than 80% of inherited breast and ovarian cancers. Alternative splicing plays a role in modulating the subcellular localization and physiological function of this gene. Many alternatively spliced transcript variants, some of which are disease-associated mutations, have been described for this gene, but the full-length natures of only some of these variants has been described. A related pseudogene, which is also located on chromosome 17, has been identified.
BRCA1/BRCA2-containing complex, subunit 1
, RING finger protein 53
, breast and ovarian cancer susceptibility protein 1
, breast and ovarian cancer sususceptibility protein 1
, breast cancer type 1 susceptibility protein
, protein phosphatase 1, regulatory subunit 53
, BRCA1 homologue
, breast cancer type 1 susceptibility protein homolog
, breast cancer 1, early onset
, BRCA1 homolog
, breast and ovarian cancer susceptibility protein
, breast cancer associated 1